List of Excipients in Branded Drug K-TAB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	K-TAB	potassium chloride	0074-3278	.ALPHA.-TOCOPHEROL
AbbVie Inc	K-TAB	potassium chloride	0074-3278	CASTOR OIL
AbbVie Inc	K-TAB	potassium chloride	0074-3278	D&C YELLOW NO. 10
AbbVie Inc	K-TAB	potassium chloride	0074-3278	ETHYLCELLULOSE

K-TAB Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

K-TAB is a potassium chloride extended-release tablet used to prevent or treat hypokalemia. Its commercial value is driven less by active-ingredient differentiation than by release control, gastrointestinal tolerability, tablet size, dose flexibility, manufacturing cost, and substitution status. The original product has no meaningful modern patent barrier. The strongest opportunities are generic or branded-generic versions with improved swallowability, lower gastrointestinal burden, reliable dissolution, and flexible 10 mEq and 20 mEq dosing.

What is K-TAB and how does its formulation work?

K-TAB contains potassium chloride in an extended-release oral tablet. The product is intended to release potassium gradually rather than deliver the entire potassium load immediately.

A standard K-TAB tablet contains:

Strength	Potassium chloride	Elemental potassium
10 mEq	750 mg	10 mEq, approximately 390 mg potassium
20 mEq	1,500 mg	20 mEq, approximately 780 mg potassium

The clinical formulation challenge is substantial. Potassium chloride is highly water-soluble, and an uncontrolled tablet can produce a concentrated local potassium load in the gastrointestinal tract. Extended release therefore depends on a matrix or coating system that slows dissolution while maintaining acceptable bioavailability.

K-TAB is swallowed whole with water. The product labeling warns against crushing, chewing, or sucking the tablets because mechanical disruption can alter release and increase gastrointestinal exposure.[1]

Which excipients are strategically important in K-TAB?

The principal excipient functions in a potassium chloride extended-release tablet are:

Excipient function	Commercial purpose
Hydrophobic matrix former	Slows water penetration and potassium chloride diffusion
Film former or polymeric coating	Controls surface erosion and release rate
Binder	Provides tablet strength despite the high drug load
Glidant	Improves powder flow during compression
Lubricant	Prevents sticking and tooling problems
Porosity modifier	Adjusts dissolution and release uniformity
Filler or diluent	Controls tablet size, hardness, and manufacturability
Colorant or opacifier	Supports product identification and stability

Public labeling for potassium chloride extended-release products identifies excipient systems that can include waxy or fatty materials, cellulose-based polymers, povidone, silicon dioxide, magnesium stearate, and related tableting agents. Exact composition is product-specific and should not be assumed to be identical across K-TAB, Klor-Con, K-Dur, and generic products.[1-3]

The key formulation issue is excipient interaction with potassium chloride loading. Because potassium chloride represents most of the tablet mass, there is limited room for conventional fillers. The formulation must achieve release control with a relatively small excipient fraction.

What excipient strategy best supports a K-TAB generic?

A viable generic strategy should prioritize a robust release-controlling system over an exact qualitative and quantitative excipient copy.

Hydrophobic matrix strategy

A hydrophobic matrix using waxes, fatty alcohols, fatty acids, or hydrophobic polymers can reduce water penetration and control potassium release. This approach has four commercial advantages:

1. It uses relatively low-cost excipients.
2. It is compatible with high drug loading.
3. It can be manufactured with conventional wet or dry granulation and compression equipment.
4. It can support a stable, non-enteric extended-release profile.

The main risks are batch-to-batch dissolution variability, sensitivity to compression force, and incomplete release under changing gastrointestinal conditions.

Polymer-coated or multiparticulate strategy

A polymer-coated system can provide tighter control over drug release. Multiparticulate potassium chloride systems may also reduce the risk of a single large tablet fragment producing concentrated potassium exposure.

This approach can support:

• Smaller unit doses;
• Sprinkle or suspension presentations, if clinically and regulatorily validated;
• More consistent dissolution;
• Improved flexibility for patients who cannot swallow large tablets.

The disadvantages are higher manufacturing complexity, more demanding coating controls, and possible regulatory questions if the dosage form differs materially from the reference product.

Direct-compression strategy

Direct compression can reduce manufacturing cost, but it is difficult to optimize for a high-load, highly soluble salt. The development team must control:

• Segregation;
• Tablet capping and lamination;
• Sticking to tooling;
• Hardness variation;
• Dissolution sensitivity to compression force;
• Uniformity across commercial-scale batches.

A dry-granulated or roller-compacted process may offer a better balance between cost and process control.

What formulation patents protect K-TAB?

K-TAB is an old potassium chloride product, and its original formulation protection has expired. The product does not present the type of active patent estate associated with newer small molecules or biologics.

Are there current Orange Book patents for K-TAB?

K-TAB is not commercially protected by a modern, high-value Orange Book patent position. The commercial product is generally relevant to an ANDA pathway rather than a 505(b)(2) or new chemical entity strategy.

For a current diligence review, the relevant regulatory records are:

• FDA Orange Book patent and exclusivity listings;
• Drugs@FDA approval history;
• The current K-TAB prescribing information;
• FDA product-specific guidance, if available;
• Abbreviated New Drug Application approvals and therapeutic-equivalence listings.[4-6]

The principal legal risk is therefore not blocking patent protection. It is regulatory approval, bioequivalence, manufacturing consistency, product liability, and market access.

Does K-TAB have method-of-use patent protection?

There is no commercially significant modern method-of-use patent position associated with the ordinary use of potassium chloride extended-release tablets for hypokalemia. The therapeutic use is established and genericized.

A new method-of-use patent would require a genuinely differentiated clinical use, such as a specific patient population, dosing protocol, or combination regimen. Routine potassium replacement would not provide a credible basis for new exclusivity.

When does K-TAB lose exclusivity?

K-TAB has already lost the exclusivity that would prevent ordinary generic competition. Potassium chloride is a long-established active ingredient, and the product has been marketed for decades.

The relevant commercial conclusion is:

Exclusivity category	K-TAB position
New chemical entity exclusivity	Expired or not applicable
Orphan exclusivity	Not applicable
Pediatric exclusivity	Not commercially relevant to current entry
Patent-based exclusivity	No meaningful current barrier
Orange Book patent litigation exposure	Low relative to newer branded products
Generic substitution	Available where an approved therapeutically equivalent product is listed

Generic applicants would normally pursue a 505(j) ANDA. A Paragraph IV certification would have limited strategic value if no unexpired listed patent blocks approval. A Paragraph III certification or certification that no relevant patent exists would be more consistent with an old, unprotected product, subject to the current Orange Book record.[4]

What regulatory requirements apply to a K-TAB generic?

The product is a complex oral extended-release dosage form. Approval requires more than demonstrating that the active ingredient is potassium chloride.

The applicant must establish:

• Pharmaceutical equivalence;
• Appropriate strength and dosage form;
• Bioequivalence under the applicable FDA standard;
• Comparable extended-release performance;
• Acceptable dissolution across relevant media;
• Stability throughout the proposed shelf life;
• Manufacturing process control;
• Labeling consistent with the reference product;
• Appropriate evaluation of dose dumping and mechanical disruption risks.

FDA may assess fed and fasted pharmacokinetics, in vitro dissolution, and product-specific performance characteristics. For an extended-release salt, dissolution can be particularly important because small changes in coating thickness, matrix porosity, granule size, or compression force can change the release profile.

The product also must address potassium chloride-specific safety risks. Excessive or rapid potassium delivery can contribute to hyperkalemia and gastrointestinal injury. A formulation that releases too slowly can create underexposure and treatment failure.

What commercial opportunities exist for K-TAB reformulation?

The most attractive opportunities are differentiated dosage forms that address known limitations of conventional potassium chloride tablets.

Smaller tablets and improved swallowability

Potassium chloride tablets are physically large because the active ingredient has a high dose-to-mass relationship. A 20 mEq tablet contains 1.5 grams of potassium chloride before excipients.

Commercial options include:

• Higher-density tablets;
• Bilayer tablets;
• Smaller multiparticulate units;
• Two 10 mEq units instead of one 20 mEq unit;
• Mini-tablets in capsules;
• Controlled-release granules.

A smaller unit may improve adherence, particularly among older adults and patients taking multiple medications.

Lower gastrointestinal burden

Potassium chloride can cause nausea, abdominal discomfort, diarrhea, and other gastrointestinal effects. Excipient and release design can reduce localized concentration and improve tolerability.

Potential approaches include:

• More gradual release;
• Multiparticulate distribution;
• Reduced tablet surface erosion;
• Improved dispersion after gastric transit;
• A formulation that avoids a sharp early dissolution peak.

Any tolerability claim would require clinical support. In vitro dissolution alone would not establish superior gastrointestinal performance.

Liquid, sprinkle, and orally dispersible products

Patients with dysphagia, feeding tubes, or post-surgical restrictions represent an identifiable opportunity. A liquid or sprinkle product could compete with conventional tablets if it can deliver controlled release without clogging feeding tubes or producing excessive potassium concentration.

The regulatory pathway may differ depending on the formulation. A materially different dosage form could require a 505(b)(2) application rather than a straightforward ANDA, particularly if equivalence to the tablet cannot be demonstrated through conventional methods.

Combination products

A potassium chloride product could be packaged or clinically positioned with diuretics that commonly produce potassium depletion, including loop and thiazide diuretics. A fixed-dose combination would face dosing rigidity and clinical complexity, but co-packaged regimens could offer a lower regulatory burden than a new fixed-dose combination.

The commercial opportunity is stronger in adherence packaging than in a new combination tablet. Potassium requirements vary substantially by patient, renal function, serum potassium level, and diuretic dose.

Which companies compete with K-TAB?

K-TAB competes with generic potassium chloride extended-release products and other branded products, including:

• Klor-Con;
• K-Dur;
• Micro-K;
• Generic potassium chloride extended-release tablets;
• Potassium chloride oral solutions;
• Potassium chloride powders or effervescent products in selected markets.

The competitive distinction is usually based on:

Attribute	Commercial impact
10 mEq and 20 mEq availability	Supports titration and prescribing flexibility
Tablet size	Affects adherence and dispensing preference
Release technology	Influences dissolution and tolerability
Unit price	Drives pharmacy substitution
Supply reliability	Matters during shortages or manufacturing interruptions
Therapeutic-equivalence rating	Determines substitution potential
Packaging	Supports institutional and retail dispensing
Tube or sprinkle compatibility	Expands use in dysphagia populations

K-TAB does not have a durable biologic-style competitive moat. Biosimilar risk is not relevant because potassium chloride is a synthetic small-molecule salt, not a biologic.

What patent litigation and settlement risks affect K-TAB?

Patent litigation risk is low. The product has no obvious current blockbuster-style patent dispute, and ordinary generic entry would not normally generate a commercially material Paragraph IV settlement structure.

The more relevant disputes would involve:

• FDA approval or therapeutic-equivalence determinations;
• Product-specific dissolution requirements;
• Labeling differences;
• Manufacturing defects;
• Supply contracts;
• Trademark or trade-dress issues;
• Alleged infringement of newly developed reformulation patents.

A reformulated K-TAB competitor could create its own patent estate around coating composition, multiparticulate architecture, manufacturing parameters, or a specific release profile. Those patents would protect the reformulation, not the underlying potassium chloride product.

How strong is the K-TAB patent estate?

The legacy patent estate is weak as a barrier to entry.

Patent-estate factor	Assessment
Active ingredient claims	None of practical commercial value
Basic therapeutic-use claims	Expired or unavailable
Legacy formulation claims	Likely expired
Current blocking patents	No meaningful barrier indicated
Manufacturing know-how	Potentially relevant but difficult to enforce broadly
Trade secrets	Could protect process parameters and scale-up knowledge
Reformulation opportunity	Available if supported by inventive technical effects

The principal defensible asset is likely know-how rather than patent exclusion. Important know-how may include coating weight, granulation endpoint, compression force, dissolution-control methods, and stability management.

What revenue exposure does K-TAB create?

K-TAB is not generally reported as a separately disclosed revenue product. Revenue exposure is therefore more relevant to product-line economics than to a publicly visible brand forecast.

Potential revenue pools include:

• Retail generic prescriptions;
• Hospital and institutional contracts;
• Long-term-care facilities;
• Specialty pharmacy dispensing;
• Low-cost branded generics;
• Private-label products;
• Reformulated dysphagia products;
• Supply agreements with integrated health systems.

The standard tablet market is price-sensitive. Margin expansion is more likely through manufacturing efficiency, reliable supply, differentiated dosage forms, or institutional contracting than through premium pricing for the conventional tablet.

What is the best commercial strategy for a K-TAB competitor?

A practical strategy is to launch a therapeutically equivalent 10 mEq and 20 mEq product with:

1. A robust hydrophobic or polymer-controlled release system;
2. Low-cost, widely available excipients;
3. Tablet dimensions equal to or smaller than the reference product;
4. Strong dissolution reproducibility;
5. Multiple packaging configurations;
6. Reliable supply for retail and institutional customers;
7. A separate reformulation program for dysphagia and feeding-tube patients.

The conventional ANDA product offers the fastest path to market but limited pricing power. A multiparticulate or sprinkle product offers more differentiation but carries greater regulatory and development cost. A company with manufacturing scale should pursue the standard generic first and use the same release technology as the platform for a differentiated dosage form.

Key Takeaways

• K-TAB is an old potassium chloride extended-release tablet with no meaningful modern exclusivity barrier.
• The formulation problem is release control in a high-drug-load, highly soluble salt.
• Hydrophobic matrices, polymer coatings, and multiparticulate systems are the main excipient platforms.
• The strongest commercial differentiators are tablet size, gastrointestinal tolerability, dissolution consistency, and supply reliability.
• Generic entry would generally proceed through the 505(j) ANDA pathway.
• Paragraph IV litigation and settlement risk is low unless a new reformulation patent is asserted.
• Biosimilar competition is irrelevant.
• The best near-term opportunity is a cost-efficient therapeutically equivalent generic.
• The best higher-margin opportunity is a smaller, multiparticulate, sprinkle, liquid, or feeding-tube-compatible formulation.
• Manufacturing know-how may have more practical value than the legacy K-TAB patent estate.

FAQs

Can K-TAB excipients be copied in an ANDA?

An ANDA applicant generally does not need to duplicate every excipient in the same qualitative and quantitative composition. The proposed product must meet applicable pharmaceutical equivalence, bioequivalence, safety, stability, and dissolution requirements.

Is potassium chloride extended release difficult to manufacture?

Yes. The active ingredient has a high drug load and high water solubility. Small changes in granulation, compression, coating, or excipient distribution can affect release performance.

Can K-TAB be reformulated as a capsule?

A capsule containing controlled-release pellets or mini-tablets could be commercially attractive, but the dosage form may require a regulatory pathway different from a conventional tablet ANDA if equivalence cannot be established using standard methods.

Are potassium chloride formulations eligible for 180-day generic exclusivity?

A first applicant may qualify for 180-day exclusivity if it satisfies the statutory requirements, including an appropriate Paragraph IV certification and timely commercial launch. That opportunity depends on the current Orange Book and ANDA filing history, not on K-TAB's age alone.

Can a new excipient create patent protection around a potassium chloride product?

An excipient alone is unlikely to create strong protection. Patent value would depend on a non-obvious formulation architecture, measurable technical advantages, and claims directed to the combination, release profile, manufacturing method, or differentiated clinical use.

References

1. U.S. Food and Drug Administration. (n.d.). K-TAB potassium chloride extended-release tablets prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Potassium chloride extended-release tablets prescribing information. DailyMed.

3. U.S. Pharmacopeia. (2023). Potassium chloride extended-release tablets monograph. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.

6. U.S. Food and Drug Administration. (2017). Development of extended-release tablets and capsules for oral administration: Guidance for industry. FDA.